ClinicalTrials.gg
CompletedNCT03984331KereburnUpdated Jul 6, 2022

Fish Skin Compared to Cadaver Skin as Temporary Cover for Full Thickness Burns

An interventional study of Fish skin and Cadaver skin in Burns, sponsored by Kerecis Ltd.. Completed at 1 site in United States. Open to participants aged 22 Years to 75 Years. Per ClinicalTrials.gov, last updated 2022-07-06.

Sponsored by Kerecis Ltd. (part of Coloplast A/S) · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Jun 2021, 5 years 5 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
5
Allocation
Randomized
Ages
22 Years to 75 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 336 studies in Burns with a site in United States — 40 open to participants now, 52 under way, 5 of them phase 3. Burns · United States.

Enrollment
225th of 272
5 · median 26
Started
2019
with 19 others
No phase
152 of 336
14 open now
Registered
226th of 336
by date

Among the 336 studies in Burns with a site in United States, this one is the 225th largest by enrollment of the 272 interventional ones that give a count, is one of 20 that started in 2019, is one of 152 with no phase, and was the 226th registered.

Burns

906 studies on the registry are indexed under Burns; 165 are open to participants now.

Browse Burns studies →

Open to participants now

40 of the 336 studies in Burns with a site in United States are open now. Recruiting first, the newest first:

35 more — sign in →

All 40 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 85 Burns studies recruiting now, 38 (45%) set no upper age limit and 38 (45%) stop at 75 or younger; 17 take children under 18; 10 take healthy volunteers.

This study: 22 Years to 75 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 336 studies in Burns with a site in United States, or all of them as a file.
02

Study summary

Objectives and rationale: Optimal burn management involves removing all the dead or burned tissue as early as feasible and cover with an autograft called split thickness skin graft (STSG) taken from the patient. This procedure creates a new wound on the patient and sometimes, when the burn covers very large portion of the patient body, there is a lack of healthy skin to use for this purpose. Under those circumstances, donated cadaver skin is used as a temporary coverage until the patient´s own donor site wound has healed enough to be used again.

The proposed clinical study aims to determine if treatment with fish skin is an alternative to cadaver skin as a temporary coverage for debrided full-thickness burns prior to STSG in terms of autograft take, time to heal, quality of healing (scarring), pain and adverse effects.

Read the detailed description

Mortality after severe burns has diminished during the last decades and survival is no longer considered the primary end point of care. More attention is paid to the final functional and cosmetic outcome of the affected area but outcomes are still far from optimal. For the time being, one of the main goals in burn treatment is to achieve reduced scar formation from the time of injury. A temporary or permanent covering of the wound bed should be achieved at the time of excision. In burn wounds the gold standard is to use split thickness skin graft, or STSG, which includes epidermis, basement membrane, and a part of upper dermis. Yet the use of skin grafts has many shortcomings: there is only a limited amount of skin available for grafting, the donor sites are susceptible to infections, to pain, to pigmentation changes, and to scarring especially when re harvested. Therefore, for complicated burns, initial treatment is often with temporary coverage where cadaver skin has been the accepted standard of care.

In recent years there has been progress in the development of advanced wound care products. This has resulted in a third generation of wound treatment, known as acellular dermal grafts or skin substitutes.

Aims The goal of this clinical trial is to demonstrate that fish skin is an alternative to cadaver skin as early cover before STSG in burn wounds. This trial will be open to patients who are scheduled to receive meshed STSG of any ratio. Fish skin or cadaver skin will be applied after initial debridement in order to prepare the wound area for STSG.

5 to 10 patients will be prospectively enrolled and two burn sites on their body will randomized to initial treatment after debridement with either fish skin or cadaver skin for 7+/-3 days. After the initial treatment, the test sites will be grafted with STSG.

The histological differences and the functional outcomes will be assessed for 12 months.

Products will be applied by experienced burn surgeons at a burn center. At approximately Day 7, or when the treating physician deems the wound to be ready for grafting, the products will be removed. Prior to grafting, a second blinded burn surgeon will assess the burn wound bed.

Important dates for blinding are on Day 7 prior to STSG treatment and on Days 14, 21 and 28 for graft take, epithelialisation and wound closure. Scar assessment at 3 and 12 months via the Vancouver Scar Sale will also be fully blinded.

Key interventions:

Randomized to either cadaver skin or fish skin after initial debridement Two areas each of 10-20 x 7 cm side by side. Other areas will be treated as per local Standard of care (SOC). Concomitant medications will be given, e.g. painkiller, antibiotics, as needed.

Wound dressings changed approximately every three days until allograft or xenograft removal.

Approximately one week after placement the fish skin and cadaver allografts removed as required.

Subsequent meshed autograft placement if donor sites are available. Autografts covered with secondary antimicrobial/silver dressing and dressings approximately every 3 days until healed.

Autografts monitored for adherence, color, autograft take, and visual signs of infection.

During the operation, a 3 or 4 mm punch biopsy will be harvested from the excised wound bed before covering with any material.

03

Conditions studied

  • Burns

Browse trials for

Keywords

  • Fish skin
  • Full thickness burn
  • Burns
  • Cadaver Skin
  • Split Thickness Skin Graft
  • Temporary Cover
  • Blaze
  • Kerecis
04

Who can participate

Ages eligible
22 Years to 75 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Participant or legally authorized representative is willing and able to give for participation in the clinical trial.

    • Patients from 22 to 75 years of age. Acute full thickness burn wounds outside the following areas; facial, genital and across joints, requiring widely meshed skin grafting or staging of STSG treatment due to insufficient healthy donor sites.
    • Maximal Total Body Surface Area (TBSA) of 50% full thickness burns
    • Able (in the Investigators opinion) and willing to comply with all clinical trial requirements.
    • Willing to allow his or her General Practitioner and consultant, if appropriate, to be notified of participation in the clinical trial.

Exclusion criteria

Exclusion Criteria:

  • Declined consent

    • patients or patients receiving immunosuppressive therapy
    • Presently participating in another clinical trial
    • Patient actively taking or cytostatic medications
    • Persons with immune deficiency because of disease or iatrogenic-
    • Any other significant disease or disorder which, in the opinion of the Investigator, may either put the participants at risk because of participation in the clinical trial, or may influence the result of the clinical trial, or the participant's ability to participate in the clinical trial.
    • Patient has known allergy to fish. (Shell fish allergy is not a )
    • Exclusion areas are, facial, genital and across joints.
    • Female participants who are pregnant, breast feeding or planning pregnancy during the course of the clinical trial
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
5 participants (actual)

Study arms

  • Experimental
    Fish skin

    All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only fish skin.

    Device: Fish skin

  • Active comparator
    Cadaver skin

    All patients will receive both treatments, fish skin and cadaver skin, as early cover after early debridement. This group of wounds will receive only cadaver skin.

    Device: Cadaver skin

Interventions

  • DeviceFish skin

    One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive fish skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.

    Also known as: Marigen TM, Kerecis Omega3 Burn

  • DeviceCadaver skin

    One out of two adjacent burn sites of 10-20 cm x 7cm surface area will be randomized to receive cadaver skin as early cover. Each patient thus serves as his/her own control. After 7 +/- 3 days the burn site will receive a meshed split thickness skin graft.

06

What researchers measure

Primary outcomes

  1. Proportions of wounds that have healed

    Wounds which have reached at least 95% epithelialization

    Time frame: At 3 weeks days after STSG

Secondary outcomes

  1. Percentage of wound area exhibiting graft failure

    The proportion of the wound area in which the graft does not take

    Time frame: At 2 weeks after STSG

  2. Full epithelialization of wound

    Number of wounds fully epithelialized

    Time frame: At 2 weeks after STSG

  3. Scarring estimated with the Vancouver Scar Scale (VSS)

    Vascularity (0-3), pigmentation (0-3), pliability (0-3), height (0-3), Total score;0=Best, 12=worst

    Time frame: At 12 months after STSG

  4. Inflammation profiling of wound punch biopsies as assessed by histology

    Histological analysis of punch wound biopsies via standard H\&E staining, or staining for known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)

    Time frame: Before STSG, 2 and 3 weeks and 12 months after STSG

  5. Average number of antibiotics treatments per patient

    Average number of antibiotics treatments per patient

    Time frame: At all treatments appointments until 4 weeks after STSG

  6. Pain assessed by the Visual Analog Scale (VAS) before and after dressing changes

    Pain by the Visual Analog Scale (VAS) on a scale of 0-10, 0=no pain, 10= pain as bad as it could be

    Time frame: At all treatments appointments until 3 weeks after STSG

  7. Bleeding time

    Average time in seconds to achieve hemostasis during dressing changes

    Time frame: At all treatments appointments until 3 weeks after STSG

  8. Dermatitis

    Incidence of dermatitis

    Time frame: At all treatments appointments until 3 weeks after STSG

  9. Ease-of-use

    Ease-of-use as judged by attending physician on a VAS scale of 0=extremely difficult to use to 10=Very easy to use

    Time frame: Day 0 when grafts are initially applied after debridement

  10. Incidence of hematoma

    Nr of wounds which develop a hematoma

    Time frame: At all treatments appointments until 3 weeks after STSG

  11. Inflammatory profiling of wound punch biopsies as assessed by mass spectrometry

    Mass spectrometry analysis of punch wound biopsies, investigating known inflammatory markers (TNF-alpha, IL-1b, IL-6, IL-8)

    Time frame: Before STSG, 2 and 3 weeks and 12 months after STSG

07

Study locations

1 site
  • Burn Center at Medstar Washington Hospital Center
    Washington, District of Columbia 20010, United States
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Feb 2019 to primary completion in Jun 2021, 27 months.

Of 29 industry-sponsored interventional studies with no phase under Burns, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 27. This study's 27 months is above that.

Counting every sponsor, half of 240 studies reached it within 15 months; a quarter within 6 and three quarters within 38.

How these figures are worked out, and which studies are left out of them.

Registered
Jan 10, 2019
First posted
Jun 13, 2019
StartActual
Feb 14, 2019
Primary completionActual
Jun 8, 2021
CompletionActual
Sep 21, 2021
Last update
Jul 6, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jul 6, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT03984331
Lead sponsor
Kerecis Ltd.
Collaborators
MedStar Health
Responsible party
Sponsor
First posted
Jun 13, 2019
Start date
Feb 14, 2019
Primary completion
Jun 8, 2021
Completion
Sep 21, 2021
Last update
Jul 6, 2022

Study contacts

Jeffrey W. Shupp, MD
principal investigator · Medstar Washington Hospital Center

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jul 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion